Michael D Kaufman

This inventor holds 53 USPTO granted patents and 32 published patent applications, plus 6 CIPO patents and 11 EPO patents, primarily in Kinase Inhibitors. Top assignees: Deciphera Pharmaceuticals, LLC, University of Pennsylvania, Eli Lilly and Company. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael D Kaufman. Retrieved from https://idiyas.com/inventor/michael-d-kaufman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 32)

% Patents Active = 75.5

CIPO Patents = 6 (Patent Applications = 10)

EPO Patents = 11 (Patent Applications = 24)

Average Co-Inventor Count = 3.6

ph-index = 27

Forward Citations = 1,624(Granted Patents)

Location History:

Philadelphia, PA (US) (1998 - 2000)
Lawrence, KS (US) (2010 - 2021)
Waltham, MA (US) (2021 - 2024)

Company Filing History:

49 out of 99

Deciphera Pharmaceuticals, LLC

patents

4 out of 2,659

University of Pennsylvania

patents

2 out of 4,517

Eli Lilly and Company

patents

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

CSF-1R Inhibitors

Kinase Inhibitors

Cancer Treatment

Dihydronaphthyridines

Pyridone Amides

RAF Inhibitors

Amorphous Formulations

Anti-Cancer Activities

Solid State Forms

N-acyl Ureas

Triazol-5-ones

Cyclopropyl Amides

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12708617 - AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF (2026-08-18),

2. 12686672 - CSF-1R inhibitors and methods of use thereof (2026-07-21),

3. 12643883 - Solid state forms of a kinase inhibitor (2026-06-02),

4. 12617775 - Processes of making CSF-1R inhibitors and methods of use thereof (2026-05-05),

5. 12528787 - Solid state forms of a kinase inhibitor (2026-01-20),

6. 12509443 - CSF-1R inhibitors and methods of use thereof (2025-12-30),

7. 12318374 - Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2025-06-03),

8. 12226406 - Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2025-02-18),

9. 12213968 - Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2025-02-04),

10. 12213967 - Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2025-02-04),

11. 12064422 - Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2024-08-20),

12. 12023328 - Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2024-07-02),

13. 11969415 - (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2024-04-30),

14. 11918564 - Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2024-03-05),

15. 11911370 - Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea (2024-02-27),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with a detailed article about the inventor Michael D Kaufman from Lawrence, KS (US), who holds 40 patents.

Title: Unveiling the Inventor Extraordinaire: Michael D Kaufman

Introduction:

Meet Michael D Kaufman, a prolific inventor hailing from Lawrence, KS, who has made significant contributions to the field of pharmaceuticals and biotechnology through his groundbreaking innovations.

Latest Patents:

Among his impressive portfolio of 40 patents, Michael D Kaufman's latest inventions center around the development of compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea. These compositions have shown promise in treating disorders related to the activity of the c-KIT and PDGFRα kinases, including their oncogenic forms.

Career Highlights:

Having worked with esteemed organizations such as Deciphera Pharmaceuticals, LLC and the University of Pennsylvania, Michael D Kaufman has honed his skills and expertise in the pharmaceutical industry. His innovative spirit and dedication to advancing medical treatments have led to the successful development of multiple patented inventions.

Collaborations:

Throughout his career, Michael D Kaufman has collaborated closely with talented individuals in the industry, including coworkers Daniel L Flynn and Scott Bone. Together, they have synergized their skills to drive innovation and bring transformative solutions to the forefront of medical research.

Conclusion:

In conclusion, Michael D Kaufman stands as a true visionary in the realm of pharmaceutical inventions, with his inventive prowess and deep understanding of biochemistry paving the way for revolutionary treatments. His patents serve as a testament to his unwavering commitment to advancing healthcare and improving the lives of many.

If you need more information or have any specific requests, feel free to ask!

Profile summary based on public USPTO records.